Menopause Test

A 30-plus biomarker assessment designed for women experiencing perimenopause or menopause symptoms, covering female hormones, bone health, heart health, iron status, thyroid function, and nutritional markers. Provides data to contextualise symptoms and inform conversations about hormone replacement therapy.

The hormonal transition surrounding menopause affects far more than reproductive function. Declining oestrogen influences cardiovascular risk, bone density, thyroid metabolism, iron utilisation, and nutrient absorption — yet many women navigate this period with limited data about what is actually happening in their body. This panel addresses that gap with 30-plus markers spanning the clinical domains most affected by menopausal hormonal changes. The female hormone component captures the key reproductive markers — FSH, LH, oestradiol — that characterise where an individual sits on the perimenopause-to-postmenopause continuum. Bone health markers are particularly relevant because oestrogen decline accelerates bone mineral loss, and early identification of this trend allows for timely intervention. Heart health markers are included because cardiovascular risk rises substantially after menopause as the protective effects of oestrogen on lipid metabolism diminish. Iron status, thyroid function, and nutritional health round out the panel, covering the metabolic shifts that commonly accompany this transition. At 154 pounds, this assessment provides a cost-effective data set for women who want to understand their symptoms in biological context — whether to validate a decision about HRT, monitor the effects of treatment already in progress, or simply confirm that symptoms are hormonally driven rather than indicating other health concerns.